Glenmark Pharmaceuticals Inc., USA has launched Olanzapine for Injection, 10 mg/vial, Single-Dose Vial in the United States market. The product is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa IntraMuscular Injection 10 mg/vial, of Cheplapharm Registration GmbH. This launch strengthens Glenmark's injectables portfolio and expands its presence in the institutional channel.

Product and Market Details

The introduction targets a market segment with significant commercial value. According to IQVIA sales data for the 12-month period ending May 2026, the Zyprexa IntraMuscular Injection market achieved annual sales of approximately $25.4 million.

Strategic Significance

Marc Kikuchi, President & Business Head, North America, stated that the launch underscores the company's strategic focus on growing a robust injectables portfolio. The move reflects a commitment to expanding access to quality and affordable treatment options for patients and healthcare providers. Glenmark's product is approved for the indications listed in its approved label.

Glenmark Pharmaceuticals has advanced its multi-country Phase 3 clinical trial for Trastuzumab rezetecan (SHR-A1811), targeting patients with platinum-resistant ovarian cancer (PROC). India has become the first country in Glenmark's licensed markets to initiate patient enrollment, following approval from the Drugs Controller General of India (DCGI). The company also plans to enroll patients in Australia and South Korea, subject to regulatory approvals in those markets.

Trial Design and Collaboration

The randomized, controlled, multi-centre Phase 3 trial is designed to evaluate the efficacy, safety, and pharmacokinetics of the HER2-targeted antibody drug conjugate (ADC). The study is aligned with Jiangsu Hengrui Pharmaceuticals Co. Ltd.'s ongoing parent Phase 3 trial in China. This collaboration aims to generate clinically relevant data across diverse patient populations to support the development of the therapy across Glenmark's licensed markets.

In September 2025, Glenmark entered into an exclusive collaboration and license agreement with Jiangsu Hengrui Pharmaceuticals Co., Ltd. for Trastuzumab rezetecan. Under the agreement, Glenmark holds exclusive rights to develop and commercialize the asset worldwide, excluding Mainland China, the Hong Kong SAR, the Macao SAR, Taiwan Region, USA, Canada, Europe, Japan, Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, and Uzbekistan.

Clinical Development of Trastuzumab Rezetecan

Trastuzumab rezetecan (SHR-A1811) is a HER2-targeted first-in-class antibody-drug conjugate developed by Hengrui Pharma. The drug addresses challenges posed by HER2-overexpressing tumors found in various cancer types, including breast, gastric, and colorectal cancers. The following table outlines the key regulatory and developmental milestones achieved by the asset:

To date, Trastuzumab rezetecan has been included in the NMPA's Breakthrough Therapy Designation list for nine indications, covering NSCLC, breast cancer, gastric or gastroesophageal junction adenocarcinoma, colorectal cancer, biliary tract cancer, and gynecologic malignancies.

Addressing Unmet Medical Need

Platinum-resistant ovarian cancer remains a difficult-to-treat disease with limited treatment options and poor outcomes. Ovarian cancer is the eighth most common cancer among women worldwide, with India ranking among the countries with the highest number of cases and deaths globally. Many patients treated with available platinum-based therapies develop recurrence and subsequent platinum resistance, underscoring the need for novel targeted therapies such as Trastuzumab rezetecan.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE935A01035/b813caa361b148f6.pdf